OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”
OS Therapies Incorporated (OSTX)
Company Research
Source: Business Wire
ROCKVILLE, Md. & NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical stage biopharmaceutical company, today announced the pricing of its initial public offering of 1,600,000 shares of common stock at a public offering price of $4.00 per share, raising gross proceeds of $6.4 million. Additionally, the Company has granted the underwriters a 45-day option to purchase up to an additional 240,000 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.The net proceeds, after deducting underwriting discounts and commissions, but before estimated expenses of the offering payable by the Company, are expected to be approximately $6.0 million. The Company intends to use the net proceeds from the offering to advance the clinical development of its product candidates – OST-HER2 and OST-tADC – and
Show less
Read more
Impact Snapshot
Event Time:
OSTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OSTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OSTX alerts
High impacting OS Therapies Incorporated news events
Weekly update
A roundup of the hottest topics
OSTX
News
- OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic CandidatesBusiness Wire
- OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical ModelsAccesswire
- OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.MarketBeat
- OS Therapies to Present at H.C. Wainright 26th Annual Global Investment ConferenceBusiness Wire
- OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment DoseBusiness Wire
OSTX
Sec Filings
- 8/28/24 - Form SC
- 8/22/24 - Form 8-K
- 8/15/24 - Form 8-K
- OSTX's page on the SEC website